MAXCYTE, INC.
MaxCyte develops cell engineering technologies and services for biopharmaceutical companies, cell and gene therapy developers, and academic and government research institutions. Its Flow Electroporation technology, marketed through the ExPERT platform, delivers molecules into cells for research, drug discovery, therapeutic development and manufacturing. The ExPERT product family includes the DTx, ATx, STx, GTx and VLx instruments, along with proprietary processing assemblies and other consumables. MaxCyte also offers gene-editing assessment services and assays through SeQure Dx, which it acquired in January 2025. MaxCyte makes money from instrument sales and licenses, sales of processing assemblies and consumables, annual instrument license fees, and milestone and commercial sales-based payments under strategic platform license agreements. The company is headquartered in Rockville, Maryland.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MXCT in the last 30 days.
See all $MXCT insider activity →MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance MaxCyte will host its third quarter 2026 earnings call today, November 10 th , at 8:30 a.m. Eastern Time Third Quarter and Recent Business Highlights: · Reports tot
MaxCyte reported Q3 2026 GAAP EPS of -$0.05, beating estimates by $0.03. Revenue grew 49.3% year-over-year to $10.2M, exceeding expectations by $2.73M. The company issued FY revenue guidance above consensus. According to the company, total revenue included $8.2M from core operations and $2.0M from SPL Program-related activities.
MaxCyte (MXCT) agreed to acquire Akron Bio for $151.8M, including cash, stock, and deferred payments. The deal, expected to close by year-end 2026, aims to nearly double MaxCyte's revenue, with Akron Bio projected to generate $28M in revenue and $7-8M in EBITDA by 2026. MaxCyte secured a $75M credit facility to fund the acquisition and operations.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MXCT (MAXCYTE, INC.). Coverage has skewed bullish: 5 bullish, 2 neutral, and 0 bearish.
Recent MXCT coverage spans earnings, technology and mergers & acquisitions.
Raised guidance and strong quarterly results suggest improved growth outlook.
Earnings beat on revenue but loss per share may limit upside.
The deal adds $28M revenue and $7-8M EBITDA in 2026, expands commercial-stage exposure and provides financing via a $75M credit facility.
The new 13D filing signals a modest ownership increase that may slightly lift the stock as investors view the stake as a vote of confidence.
Guidance beat and strong Q3 results likely support further upside.
AlphAI scores every news story that mentions MXCT with an AI model for sentiment and relevance, and aggregates insider trades from MAXCYTE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance MaxCyte will host its third quarter 2026 earnings call today, November 10 th , at 8:30 a.m. Eastern Time Third Quarter and Recent Business Highlights: · Reports tot
MaxCyte reported Q3 2026 GAAP EPS of -$0.05, beating estimates by $0.03. Revenue grew 49.3% year-over-year to $10.2M, exceeding expectations by $2.73M. The company issued FY revenue guidance above consensus. According to the company, total revenue included $8.2M from core operations and $2.0M from SPL Program-related activities.
MaxCyte (MXCT) agreed to acquire Akron Bio for $151.8M, including cash, stock, and deferred payments. The deal, expected to close by year-end 2026, aims to nearly double MaxCyte's revenue, with Akron Bio projected to generate $28M in revenue and $7-8M in EBITDA by 2026. MaxCyte secured a $75M credit facility to fund the acquisition and operations.
Liontrust Investment Partners disclosed a 5.03% stake in MaxCyte, Inc. (MXCT) after recent share transactions. The firm reported selling shares in September and purchasing over 350,000 shares on Oct. 14 at an average price of $1.26. Liontrust did not specify future plans for its investment.
MaxCyte Inc (MXCT) shares rose 25% after raising its 2026 revenue guidance to $34M from $30M-$32M, citing strong Q3 results. Q3 core revenue was $8.1M, up 26% YoY, exceeding estimates. The company also reported $1M in SPL-related revenue. Updated guidance reflects 15% YoY growth in core revenue for H2 2026.
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-en
MaxCyte (MXCT) reported Q2 2026 revenues ahead of expectations, with sequential growth driven by instrument placements, including its DTx platform. The company reduced net loss YoY and announced a multiplatform technology license partnership with Genentech, reflecting growing recognition of MaxCyte's technology. The partnership supports multiple programs and diversifies MaxCyte's revenue streams. Vertex's CASGEVY revenue grew 75% sequentially and 150% YoY, contributing to MaxCyte's SPL program-r
MaxCyte (MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays to help therapeutic developers assess off-target risks in base editing therapies. The assays aim to identify potential off-target editing sites and genetic variants, supporting regulatory compliance and clinical development. MXCT's stock closed at $1.27, down 3.79%, and is down 0.47% in premarket trading.
MaxCyte, Inc. (NASDAQ: MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays for off-target assessment in genome editing therapies. These assays, part of MaxCyte's SeQure service, aim to enhance safety evaluation for base editors, aligning with FDA guidelines. The company positions itself as a single-source provider for orthogonal nomination assays, supporting therapeutic developers in clinical development.
MaxCyte reported Q2 2026 sequential revenue growth after inventory drawdowns from a major customer and clinical program discontinuations. It signed a multi-platform enterprise partnership with Genentech and expects 2026 revenue guidance of $30m to $32m. Operating expenses fell 25% YoY. Company plans to use most of a $10m share repurchase program and expects mid-70s gross margins.
